NeuroMetrix stock carries a delisted label as revenue falls 48.61 percent

NeuroMetrix stock carries a delisted label dated September 22, 2026, while fiscal 2024 revenue fell 48.61 percent to USD 3.03 million. The figures point to a sharply smaller operating base than the USD 5.90 million reported for fiscal 2023.

Delisting changes the stock picture

Eulerpool identifies NeuroMetrix as NURO and marks the security as delisted on its page updated September 22, 2026. The same page assigns the company the ISIN US6412558800, which differs from the input identifier, so this article uses the company name and ticker without carrying that identifier forward.

For investors, the delisted label changes the practical meaning of any stock quote. The central question shifts from a daily exchange move to the status of the security and the company assets associated with the former public listing.

Revenue contracted by 48.61 percent

Historical fiscal 2024 revenue stood at USD 3.03 million, down 48.61 percent from USD 5.90 million in fiscal 2023, according to Eulerpool. The comparison is material because the decline was paired with a historical fiscal 2024 EBIT loss of USD 8.78 million and a net loss of USD 7.81 million.

Eulerpool's historical table also shows that revenue fell from USD 8.26 million in fiscal 2022 to USD 5.90 million in fiscal 2023 before reaching USD 3.03 million in fiscal 2024. That three-year sequence places the latest reported sales figure 63.32 percent below the fiscal 2022 level.

Three medical devices define the business

TopStonks describes NeuroMetrix as a medical-device company focused on nerve-function diagnosis and treatment. Its commercial portfolio included DPNCheck for peripheral neuropathy screening, ADVANCE for nerve-conduction studies and Quell, a wearable neurostimulation device for chronic pain.

The product mix explains why the company was classified in the health-care equipment and supplies industry. It also shows the distinction between the operating business and the former listed security, a distinction that matters after the delisted status dated September 22, 2026.

Stock status is the key checkpoint

NeuroMetrix stock therefore combines a delisted label with historical fiscal 2024 revenue of USD 3.03 million and a 48.61 percent year-over-year decline. The company profile remains tied to medical devices, while the former public-market status is the decisive fact for assessing NURO.